체외 독성 시험 시장 : 서비스 유형별, 기술, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The In-Vitro Toxicology Testing Market is projected to grow by USD 31.73 billion at a CAGR of 11.52% by 2032.

In-vitro toxicology testing is moving from a supporting research tool to a core decision-making platform for pharmaceutical, biotechnology, chemical, cosmetic, food ingredient, and medical device developers. The market is being shaped by validated toxicology assays, human-relevant cell models, 3D cell culture, organ-on-chip systems, high-throughput screening, and computational toxicology that reduce reliance on animal testing while improving early safety prediction.

Regulatory momentum is a central growth driver. The FDA Modernization Act 2.0 removed the statutory requirement for animal testing before human drug trials in the United States, while the European Union has enforced a full cosmetics animal testing ban since 2013 and continues to support the 3Rs principles under Directive 2010/63/EU. OECD test guidelines for skin corrosion, skin irritation, serious eye damage, eye irritation, phototoxicity, genotoxicity, and endocrine activity provide a recognized foundation for broader adoption of non-animal methods and new approach methodologies.

Transformative Shifts in the Testing Landscape

The in-vitro toxicology testing landscape is being transformed by the convergence of regulatory acceptance, ethical expectations, and scientific advances in human biology-based models. Conventional monolayer cell assays remain widely used for cytotoxicity and genotoxicity screening, but demand is accelerating for 3D spheroids, co-culture models, induced pluripotent stem cell-derived tissues, microphysiological systems, and organ-on-chip platforms that better replicate human tissue architecture, metabolism, and exposure dynamics.

End users are also changing how toxicology evidence is generated. Pharmaceutical companies are integrating in-vitro toxicology earlier in discovery to de-risk lead candidates, chemical manufacturers are using integrated approaches to testing and assessment under REACH and OECD frameworks, and cosmetics companies are relying on validated in-vitro methods because animal testing for finished cosmetic products and ingredients is prohibited in the EU. The shift favors providers that combine biological relevance, regulatory documentation, reproducibility, endpoint sensitivity, and scalable assay automation.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasing the value of in-vitro toxicology testing by connecting assay outputs with predictive models, chemical structure data, omics datasets, adverse outcome pathways, and exposure information. Machine learning supports image-based toxicity scoring, high-content screening, quantitative structure-activity relationship modeling, dose-response prediction, and prioritization of compounds for confirmatory testing. These applications are especially valuable when screening large chemical libraries, detecting subtle cellular phenotypes, or identifying mechanisms of toxicity.

The cumulative impact of AI is not the replacement of laboratory science but the creation of more efficient, transparent, and evidence-rich toxicology workflows. Leading organizations are combining AI with good laboratory practice, data provenance, model validation, and explainability requirements. Regulatory relevance depends on traceable datasets, defined applicability domains, reproducible algorithms, bias control, and alignment with OECD principles for validated computational models.

Key Regional Insights

Asia-Pacific is becoming a major hub for in-vitro toxicology testing as China, India, Japan, South Korea, Singapore, and Australia invest in biopharmaceutical R&D, contract research, cosmetics safety, advanced cell models, and regulatory science. North America remains a leading innovation center due to the presence of the FDA, NIH, EPA, established CRO networks, high biopharma research activity, and active programs such as Tox21 that demonstrate the use of high-throughput in-vitro screening for chemical safety prioritization.

Europe continues to set the global benchmark for non-animal testing through EU cosmetics restrictions, REACH requirements, ECHA guidance, OECD-aligned validation practices, and long-standing policy support for the 3Rs. Latin America is expanding adoption through pharmaceutical manufacturing, cosmetics demand, food safety testing, and regulatory modernization led by Brazil and Mexico. The Middle East is building demand through healthcare diversification, national biotechnology strategies, and research infrastructure, while Africa is at an earlier adoption stage but shows long-term potential as laboratory capacity, public health testing, and academic-industry collaboration expand.

Key Group Insights

ASEAN markets are increasingly relevant for in-vitro toxicology testing because Singapore anchors biomedical innovation while Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand pharmaceutical, food, and cosmetic production. The GCC is gaining visibility as Saudi Arabia, the UAE, and neighboring economies invest in life sciences, health security, clinical research infrastructure, and quality systems. The European Union remains the most influential regulatory group for alternative toxicology methods due to harmonized chemicals and cosmetics rules, REACH implementation, and strong 3Rs policy.

BRICS countries represent scale, manufacturing depth, and growing domestic demand, with China and India particularly important for drug development services, chemical safety testing, and biopharmaceutical research. G7 economies lead in regulatory science, advanced biomanufacturing, biomedical funding, and policy support for new approach methodologies. NATO is not a commercial regulatory bloc, but member alignment on biosecurity, medical countermeasures, and defense health research can indirectly support validated toxicology platforms for emergency preparedness and chemical threat assessment.

Key Country Insights

The United States leads through FDA regulatory modernization, NIH-supported translational science, EPA chemical testing initiatives, and a mature CRO ecosystem. Canada benefits from strong academic toxicology, biotechnology clusters, and alignment with OECD methods, while Mexico is increasingly tied to North American manufacturing, pharmaceuticals, medical devices, and quality testing networks. Brazil is the primary Latin American market due to its pharmaceutical, cosmetics, chemical, and regulatory science activities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine established life science industries with regulatory pressure to reduce animal testing, while Russia maintains demand in pharmaceuticals, chemicals, and public research despite geopolitical constraints. China and India are expanding rapidly through large CRO sectors, domestic drug pipelines, chemical manufacturing, and cosmetics and safety testing requirements. Japan and South Korea emphasize high-quality regulatory science, stem cell research, and advanced cell technologies, and Australia is recognized for biomedical research, clinical development connectivity, and OECD-aligned testing practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated assay portfolios that address high-demand endpoints such as cytotoxicity, genotoxicity, skin and eye irritation, hepatotoxicity, cardiotoxicity, immunotoxicity, neurotoxicity, and endocrine disruption. Investments should focus on assays with clear regulatory pathways, defined performance standards, reference chemicals, and documentation packages that can support submissions across OECD, FDA, EPA, EMA, ECHA, and national authority expectations.

Companies should build integrated testing strategies that combine in-vitro assays, in-silico models, exposure science, adverse outcome pathways, and targeted in-vivo testing only where required. Strategic partnerships with CROs, organ-on-chip developers, automation suppliers, biobanks, and AI analytics providers can shorten validation timelines. Leaders should also implement data governance, FAIR data principles, quality management systems, and explainable AI controls to ensure scientific credibility and regulatory confidence.

Research Methodology

The research methodology combines secondary research from regulatory bodies, standards organizations, peer-reviewed literature, patent trends, industry association materials, and publicly available institutional sources. Core sources include OECD test guidelines, FDA and EPA policy documents, European Commission and ECHA guidance, NIH and Tox21 publications, ISO quality standards, PubMed-indexed toxicology studies, and recognized scientific publications on new approach methodologies.

Market interpretation is developed through triangulation across technology adoption signals, regulatory milestones, end-user demand patterns, regional life science infrastructure, laboratory capability, and expert assessment of validated test methods. The analysis avoids unsupported market-size claims and focuses on verifiable indicators, including policy changes, recognized test guidelines, quality standards, documented assay validation, and scientific adoption of new approach methodologies.

Conclusion

In-vitro toxicology testing is positioned for sustained expansion as regulators, companies, and consumers demand safer, faster, and more human-relevant toxicity assessment. The strongest opportunities are emerging where validated assays, advanced cell models, automation, high-content imaging, and AI-enabled analytics are integrated into reproducible and regulator-ready workflows.

Competitive advantage will depend on scientific validation, data integrity, multi-region compliance expertise, and the ability to translate complex biological outputs into actionable safety decisions. Organizations that invest now in scalable, human-relevant, and evidence-based in-vitro toxicology platforms will be better prepared for the next phase of non-animal testing, new approach methodologies, and precision safety assessment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In-Vitro Toxicology Testing Market, by Service Type

• 7.1. Biochemical Assays
• 7.2. Cell Culture Assays
  • 7.2.1. Cell Line Assays
  • 7.2.2. Primary Cell Assays
• 7.3. Computational Models

8. In-Vitro Toxicology Testing Market, by Technology

• 8.1. High Throughput Screening
  • 8.1.1. Assay Based
  • 8.1.2. Imaging Based
• 8.2. Microfluidics
• 8.3. Organ On Chip
• 8.4. Three Dimensional Culture

9. In-Vitro Toxicology Testing Market, by Application

• 9.1. Cosmetics Testing
  • 9.1.1. Ocular Irritation
  • 9.1.2. Skin Irritation
• 9.2. Drug Discovery
  • 9.2.1. Lead Optimization
  • 9.2.2. Target Validation
• 9.3. Safety Assessment
  • 9.3.1. Carcinogenicity
  • 9.3.2. Cytotoxicity
  • 9.3.3. Genotoxicity

10. In-Vitro Toxicology Testing Market, by End User

• 10.1. Academic And Research Institutes
• 10.2. Contract Research Organizations
• 10.3. Pharma And Biotech

11. In-Vitro Toxicology Testing Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. In-Vitro Toxicology Testing Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. In-Vitro Toxicology Testing Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Agilent Technologies, Inc.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Bio-Techne Corporation
• 15.6. BioIVT LLC
• 15.7. Charles River Laboratories International, Inc.
• 15.8. Creative Bioarray
• 15.9. ERBC Group
• 15.10. Eurofins Scientific SE
• 15.11. Evotec SE
• 15.12. F. Hoffmann-La Roche AG
• 15.13. Gentronix Limited
• 15.14. HD Biosciences Co., Ltd.
• 15.15. INDIGO Biosciences, Inc.
• 15.16. Inotiv, Inc.
• 15.17. InSphero AG
• 15.18. Intertek Group PLC
• 15.19. Laboratory Corporation of America Holdings
• 15.20. LAUS GmbH
• 15.21. LGC Limited
• 15.22. Merck KGaA
• 15.23. Microbac Laboratories Inc.
• 15.24. Oroxcell
• 15.25. Promega Corporation
• 15.26. Qiagen N.V.
• 15.27. SGS SA
• 15.28. Thermo Fisher Scientific Inc.
• 15.29. Toxys, Inc.
• 15.30. Vimta Labs Ltd.
• 15.31. WuXi AppTec